138 related articles for article (PubMed ID: 2989276)
1. Two mechanisms for inhibition of ADP-induced platelet shape change by 5'-p-fluorosulfonylbenzoyladenosine. Conversion to adenosine, and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase.
Mills DC; Figures WR; Scearce LM; Stewart GJ; Colman RF; Colman RW
J Biol Chem; 1985 Jul; 260(13):8078-83. PubMed ID: 2989276
[TBL] [Abstract][Full Text] [Related]
2. ADP-induced platelet shape change and mobilization of cytoplasmic ionized calcium are mediated by distinct binding sites on platelets: 5'-p-fluorosulfonylbenzoyladenosine is a weak platelet agonist.
Rao AK; Kowalska MA
Blood; 1987 Sep; 70(3):751-6. PubMed ID: 3040154
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.
Mills DC; Puri R; Hu CJ; Minniti C; Grana G; Freedman MD; Colman RF; Colman RW
Arterioscler Thromb; 1992 Apr; 12(4):430-6. PubMed ID: 1558834
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of an ADP receptor mediating platelet activation.
Colman RW; Figures WR
Mol Cell Biochem; 1984; 59(1-2):101-11. PubMed ID: 6323960
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ADP-induced platelet shape change and aggregation by o-phthalaldehyde: evidence for covalent modification of cysteine and lysine residues.
Puri RN; Colman RW
Arch Biochem Biophys; 1991 May; 286(2):419-27. PubMed ID: 1910292
[TBL] [Abstract][Full Text] [Related]
6. Direct evidence for the interaction of the nucleotide affinity analog 5'-p-fluorosulfonylbenzoyl adenosine with a platelet ADP receptor.
Figures WR; Scearce LM; DeFeo P; Stewart G; Zhou F; Chen J; Daniel J; Colman RF; Colman RW
Blood; 1987 Sep; 70(3):796-803. PubMed ID: 3040157
[TBL] [Abstract][Full Text] [Related]
7. Affinity labeling of a human platelet membrane protein with 5'-p-fluorosulfonylbenzoyl adenosine. Concomitant inhibition of ADP-induced platelet aggregation and fibrinogen receptor exposure.
Figures WR; Niewiarowski S; Morinelli TA; Colman RF; Colman RW
J Biol Chem; 1981 Aug; 256(15):7789-95. PubMed ID: 6267026
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin.
Puri RN; Colman RF; Colman RW
Eur J Biochem; 1996 Mar; 236(3):862-70. PubMed ID: 8665907
[TBL] [Abstract][Full Text] [Related]
10. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets.
Macfarlane DE; Srivastava PC; Mills DC
J Clin Invest; 1983 Mar; 71(3):420-8. PubMed ID: 6298277
[TBL] [Abstract][Full Text] [Related]
11. Identification of two distinct adenosine diphosphate receptors in human platelets.
Colman RW; Figures WR; Colman RF; Morinelli TA; Niewiarowski S; Mills DC
Trans Assoc Am Physicians; 1980; 93():305-16. PubMed ID: 6264660
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of collagen-induced platelet activation by 5'-p-fluorosulfonylbenzoyl adenosine: evidence for an adenosine diphosphate requirement and synergistic influence of prostaglandin endoperoxides.
Colman RW; Figures WR; Scearce LM; Strimpler AM; Zhou FX; Rao AK
Blood; 1986 Aug; 68(2):565-70. PubMed ID: 3730618
[TBL] [Abstract][Full Text] [Related]
13. Platelet ADP receptor and alpha 2-adrenoreceptor interaction. Evidence for an ADP requirement for epinephrine-induced platelet activation and an influence of epinephrine on ADP binding.
Figures WR; Scearce LM; Wachtfogel Y; Chen J; Colman RF; Colman RW
J Biol Chem; 1986 May; 261(13):5981-6. PubMed ID: 3009439
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor.
Puri RN; Colman RW
J Cell Biochem; 1996 Apr; 61(1):97-108. PubMed ID: 8726359
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
Haslam RJ; Davidson MM; Desjardins JV
Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ATP-induced cAMP formation by 5'-p-fluorosulfonylbenzoyladenosine in NG108-15 cells.
Ohkubo S; Matsuoka I; Kimura J; Nakanishi H
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):153-9. PubMed ID: 9749999
[TBL] [Abstract][Full Text] [Related]
17. A novel method for chemical modification of functional groups other than a carboxyl group in proteins by N-ethyl-5-phenylisooxazolium-3'-sulfonate (Woodward's reagent-K): inhibition of ADP-induced platelet responses involves covalent modification of aggregin, an ADP receptor.
Puri RN; Colman RW
Anal Biochem; 1996 Sep; 240(2):251-61. PubMed ID: 8811919
[TBL] [Abstract][Full Text] [Related]
18. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
Lam SC; Guccione MA; Packham MA; Mustard JF
Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
[TBL] [Abstract][Full Text] [Related]
19. Aggregin: a platelet ADP receptor that mediates activation.
Colman RW
FASEB J; 1990 Mar; 4(5):1425-35. PubMed ID: 2407587
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.
Sugidachi A; Asai F; Yoneda K; Iwamura R; Ogawa T; Otsuguro K; Koike H
Br J Pharmacol; 2001 Jan; 132(1):47-54. PubMed ID: 11156560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
